Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
REMX VanEck Rare Earth/Strategic Metals ETF
PYPL PayPal Holdings Inc
PWZ Invesco California AMT-Free Municipal Bond ETF
PVG Pretium Resources Inc
PTY PIMCO Corporate and Income Opportunity Fund
PTA COHEN & STEERS TAX-ADV PRD SEC AND INC
PSXP Phillips 66 Partners LP
PSX Phillips 66
PSK SPDR® ICE Preferred Securities ETF
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Closing Price
$603.19
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
844,625
0

Display:

Providers:

UpdateCancel
6 providers
January 20, 2022
Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school...(PR Newswire)

Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talent Search

Over $3 Million to be Awarded in Oldest and Most Prestigious U.S. STEM Competition for High School Seniors Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science...(PR Newswire)

January 19, 2022
Second Positive Phase 3 Dupixent(R) (dupilumab) Trial Confirms Significant Improvements for Patients with Prurigo Nodularis

Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions (PR Newswire)

January 13, 2022
Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Friday, February 4, 2022, before the U.S. financial markets open. The Company will host a...(PR Newswire)

January 07, 2022
Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza(R) (evinacumab) Outside the United States

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza(R) (evinacumab) in countries outside...(PR Newswire)

January 04, 2022
Global Alzheimer's Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028

FinancialNewsMedia.com News Commentary - Alzheimer's disease is a degenerative, progressive ailment that attacks the brain's nerve cells, resulting in memory loss, behavioral changes as well as changes in thinking and language skills. During the...(PR Newswire)

December 13, 2021
Positive Phase 3 Dupixent(R) (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session

Dupixent significantly improved skin clearance and reduced overall disease severity and itch in pivotal trial that met all primary and secondary endpoints Global regulatory filings planned in the coming months, starting with the U.S. by the end of...(PR Newswire)

December 11, 2021
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma

Includes latest data for REGN5458, including in highest dose levels (200-800 mg) Among patients who responded across all dose groups (3-800 mg), there was a 90% probability of being event-free (i.e., alive without disease progression) 8 months from...(PR Newswire)

December 08, 2021
New England Journal of Medicine Publishes Positive Phase 3 Dupixent(R) (dupilumab) Results in Children with Moderate-to-severe Asthma

Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma Published results reinforce well-established safety profile of Dupixent (PR Newswire)

December 03, 2021
Regeneron to Participate in H.C. Wainwright & Co. Virtual Event

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event - Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and...(PR Newswire)

November 30, 2021
Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs

FinancialNewsMedia.com News Commentary - Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is...(PR Newswire)

Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs

FinancialNewsMedia.com News Commentary - Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is...(PR Newswire)

November 16, 2021
Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: -- Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 -- Piper Sandler 33rd Annual Healthcare Conference at...(PR Newswire)

November 15, 2021
Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year

DJSI World highlights the most sustainable companies around the world by industry Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been recognized as a global corporate responsibility leader through inclusion on the Dow Jones Sustainability World...(PR Newswire)

November 12, 2021
Regeneron Announces $3 Billion Share Repurchase Program

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company's outstanding common stock. "With the strength of our balance sheet and our business...(PR Newswire)

Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19

EC marketing authorization follows approvals in Japan, Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as...(PR Newswire)

November 11, 2021
CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the casirivimab and imdevimab antibody cocktail, known...(PR Newswire)

November 08, 2021
New Phase 3 Analyses Show That a Single Dose of REGEN-COV(R) (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 (PR Newswire)

November 04, 2021
Regeneron Reports Third Quarter 2021 Financial and Operating Results

-- Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV(R)(2) -- Third quarter 2021 EYLEA(R) U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion (PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.